<DOC>
	<DOCNO>NCT01696045</DOCNO>
	<brief_summary>The purpose study comply Pediatric Investigation Plan requirement Ipilimumab</brief_summary>
	<brief_title>Phase 2 Study Ipilimumab Children Adolescents ( 12 &lt; 18 Years ) With Previously Treated Untreated , Unresectable Stage III Stage lV Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . 12 &lt; 18 year age Previously treat untreated , unresectable Stage III Stage IV malignant melanoma Karnofsky Performance Status ( KPS ) Lansky Score â‰¥ 50 Primary Ocular Melanoma Prior therapy Cytotoxic T Lymphocyte Antigen 4 ( CTLA4 ) Programmed death 1 ( PD1 ) antagonist , Programmed cell death ligand 1 ( PDL1 ) CD137 agonists Symptomatic brain metastasis History autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>